AzTrials
AzTrials

Neurological DisordersPhase 3Nidiag-NeuroNCT01589289

Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC

A Phase 3 study testing Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test and TB POC Nucleic Acid Amplification Test (Molbio Diagnostics) in people with Neurological Disorders and Cerebral Malaria, run by Institute of Tropical Medicine, Belgium at 1 site in Democratic Republic of the Congo.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management. Read more about this study

Who is it for?
Ages 5 years and older
What is being tested?
Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test and TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
352 participants
Where
1 siteDemocratic Republic of the Congo
Study dates
Sep 2012to May 2015
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patients > 5 years-old AND
  • Altered state of consciousness (confusion to coma) OR/AND
  • Changes of sleep pattern (daytime slumber, night insomnia)OR/AND
  • Cognitive decline OR/AND
  • Changes in personality/behaviour (e.g. bouts of mania)OR/AND
  • Epileptic seizure(s)OR/AND
Show all 11Show fewer
  • Daily severe/progressive headache OR/AND
  • Meningismus (headache, neck stiffness, nausea/vomiting, photophobia)
  • Cranial nerve lesions OR/AND
  • Sensory-motor deficits or other focal neurological signs (e.g. dysphagia, dysarthria, ataxia, dystonia,...)OR/AND
  • Gait disorders (e.g. spastic or ataxic gait)

Who cannot join

  • Those unwilling or unable to give written informed consent (either directly or via proxy)
  • Those unable in the physician's opinion to comply with the study requirements
  • Neurological symptom unequivocally related with recent trauma
  • Neurological symptom as sequelae of previous well-established neurological events (e.g. stroke,…)
  • First seizure below 6 years of age (early onset seizure)

Trial locations and contacts

1 site in 1 country.

Democratic Republic of the Congo1 site
  • Reference Hospital Mosango

    Mosango, Bandundu

Other trials in Democratic Republic of the Congo

About this study

Official title: Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo

The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management. In sub-Saharan Africa, the few observational studies conducted for the past 20 years show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis etc. If left untreated, death or serious sequels occur (mortality rates were as high as 30% in the above mentioned studies), but the outcome may be favourable with timely and appropriate management.

In poor settings, such conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, they require advanced diagnostic technology, which is not available in most tropical rural settings: here, you have to rely on clinical judgment and first-line laboratory results, whose confirming or excluding powers are limited or unknown. Several rapid diagnostic tests (RDTs) have been recently developed for conditions like malaria or HIV, but their diagnostic contribution has not been evaluated within a multi-disease approach.

Read more

Thus, this research aims at improving the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC), by combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests.

The evaluation of existing algorithms and elaboration/validation of new guidelines will be described in a subsequent protocol.

Read the detailed description

The impact of neurological disorders is enormous in terms of mortality, morbidity, physical disability and psychological distress, and it is increased in low-resource settings by lack of diagnosis and of treatment facilities as well as delayed management. The frequency of neurological disorders and the pattern of causative conditions are little documented in low-resource primary care settings.In sub-Saharan Africa, the few observational studies conducted for the past 20 years, show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Where it has been investigated, up to one third of neurological admissions was related to HIV infection in some settings. Neuro-infections were also the leading aetiologies of common neurological symptoms (such as headache) in African HIV-positive patients, and autopsy studies have demonstrated that CNS infections accounted for 20% of the causes of death in HIV-positive individuals in sub-Saharan Africa.

Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis, neurosyphilis, cryptococcal meningitis or toxoplasma encephalitis etc. If left untreated, death or serious sequels usually occur; mortality rates of neurological admissions were as high as 30% in the above mentioned studies. However, outcome may be favourable with timely and appropriate management.

In resource-constrained settings more than elsewhere, such "severe and treatable" conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, neurological diagnoses frequently require advanced technology, but this is far beyond reach of most tropical rural settings, where you have to rely on clinical judgment and first-line laboratory results. However, the confirming or excluding powers of most clinical and laboratory features are limited or have never been adequately quantified, in particular in settings lacking reference diagnostic methods. Several rapid diagnostic tests (RDTs) have been developed in the last decade for conditions like malaria or HIV infection, but their diagnostic contribution has never been evaluated within a multi-disease approach. Most CNS infections with worldwide distribution affect disproportionally the (sub)-tropical regions, while others are restricted to the tropics. Also, many infections with potential neuropathogenicity belong to the group of 17 Neglected Tropical Diseases (NTDs) on which attention has been recently brought. As said above, most of them may be considered as "severe and treatable"; however, in most tropical settings, epidemiology of NTDs and other infectious diseases (IDs) is largely unknown, seriously impairing the case finding and clinical decision-making.

The aim of this research therefore is to improve the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which may present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC). This will be achieved through the elaboration and validation of new diagnostic guidelines based on epidemiological evidence, combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests, and designed with a "panoramic" (not-to-miss) approach.

In particular, the investigators hope to determine the pre-test probability of HAT and other priority neglected tropical diseases/infectious diseases in patients presenting with neurological disorders; to assess the predictive weight of clinical and first-line laboratory features in the diagnosis of HAT and other priority NTDs/IDs; to assess the sensitivity, specificity and predictive values of novel point-of-care RDTs for the diagnosis of HAT and other priority NTDs/IDs in patients with neurological disorders; and to assess the diagnostic performances of combinations of novel and existing RDTs for diagnosing HAT and other priority NTDs/IDs in patients with neurological disorders. Enrolled patients will be managed according the current standard of care in Bandundu, DRC and with the treatments locally available through health facilities/programs.

The objectives and methodology of this second step of our research (evaluation of existing algorithms and elaboration/validation of new guidelines) will be described in a subsequent protocol. Another similar study (described in another protocol) will be conducted in parallel to explore the aetiologies of prolonged fever in the same setting.

Being tested
Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test, TB POC Nucleic Acid Amplification Test (Molbio Diagnostics), TB 3-marker RDT (Tulip diagnostics), Cryptococcal Antigen Lateral Flow Assay (Immy)
Keywords
Diagnostic research, Rapid diagnostic tests, Neurological disorders, Neglected Tropical Diseases, Developing countries
Medical subject headings
Nervous System Diseases, Malaria, Cerebral, Meningitis, Bacterial, Tuberculosis, Central Nervous System, Neurosyphilis, Meningitis, Cryptococcal, Neglected Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Immunochromatographic HAT tests (DSD)Device

    Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND

  • Card Agglutination Trypanosoma TestDevice

    Also called CATT

    Card Agglutination Trypanosoma Test on whole blood and as dilution

  • TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)Device

    Also called NAAT

    TB POC Nucleic Acid Amplification Test: "microPCR handheld device" (Molbio Diagnostics PVT ltd, India)

  • TB 3-marker RDT (Tulip diagnostics)Device

    TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation

  • Cryptococcal Antigen Lateral Flow Assay (Immy)Device

    Also called CrAg-LAT

    Cryptococcal Antigen Lateral Flow Assay (Immy, USA)

Study groups in NCT01589289
Study groupRoleWhat they receive
Phase 3 RDTsExperimentalThe different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
Receives: Device: Immunochromatographic HAT tests (DSD); Device: Card Agglutination Trypanosoma Test; Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics); Device: TB 3-marker RDT (Tulip diagnostics); Device: Cryptococcal Antigen Lateral Flow Assay (Immy)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of HAT and other NTDs/IDs

    Number of patients diagnosed with HAT and other NTDs/IDs among those presenting with neurological disorders in rural hospitals of Bandundu, DRC (pre-test probability)

    Measured: 18 months

  2. Identification of reliable diagnostic tests

    Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for the respective target conditions, and identification of those that should be included in future diagnostic protocols

    Measured: 18 months

  3. Predictive values of RDTs

    Predictive values (post-test probabilities) of novel and existing RDTs, alone and in combination, for the respective target conditions within this multi-disease approach

    Measured: 18 months

  4. Identification of clinical and laboratory diagnostic indicators

    Assessment of the specificity of the different clinical and first-line laboratory features for the diagnosis of HAT and other priority NTDs/IDs in the setting, for determining those that should be included in future diagnostic protocols

    Measured: 18 months

Secondary outcomes (2)
  1. Cure rate

    Number of patients who positively respond to specific/empirical therapies, as assessed as final patient outcomes (cure, referral, sequelae, death)

    Measured: 18 months

  2. Cost-effectiveness of the diagnostic tests

    Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs/IDs in the setting

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2012 (estimated)
  2. Study startSep 2012
  3. Primary completionJan 2015
  4. Study completionMay 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
352 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01589289
Sponsor's protocol ID
WP2-01-NEU
Acronym
Nidiag-Neuro
Status last verified
Jan 2016
First submitted
26 Apr 2012
Last updated
18 Jan 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test and TB POC Nucleic Acid Amplification Test (Molbio Diagnostics) in people with Neurological Disorders and Cerebral Malaria, run by Institute of Tropical Medicine, Belgium at 1 site in Democratic Republic of the Congo.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Democratic Republic of the Congo. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of HAT and other NTDs/IDs (time frame: 18 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in